iTeos Therapeutics Files Q1 2025 10-Q
| Field | Detail |
|---|---|
| Company | Iteos Therapeutics, Inc. |
| Form Type | 10-Q |
| Filed Date | Apr 28, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, biotechnology, financials
TL;DR
iTeos Q1 2025 10-Q is in. Financials look steady, check GSK & Adimab deals.
AI Summary
iTeos Therapeutics, Inc. filed a 10-Q for the period ending March 31, 2025. The filing details financial information, including interest income from money market funds and additional paid-in capital. Key entities mentioned include GlaxoSmithKline and Adimab LLC, with whom iTeos has licensing and service agreements.
Why It Matters
This filing provides investors with an update on iTeos Therapeutics' financial health and operational activities for the first quarter of 2025, including details on their collaborations and financial instruments.
Risk Assessment
Risk Level: medium — The company operates in the highly competitive and regulated biotechnology sector, facing risks related to drug development, clinical trials, and market adoption.
Key Numbers
- N/A — Revenue (Specific revenue figures for the quarter are not detailed in the provided header information.)
- N/A — Net Income (Specific net income figures for the quarter are not detailed in the provided header information.)
- N/A — Cash Flow (Specific cash flow figures for the quarter are not detailed in the provided header information.)
Key Players & Entities
- iTeos Therapeutics, Inc. (company) — Filer
- GlaxoSmithKline (company) — Collaboration partner
- Adimab LLC (company) — Collaboration partner
- March 31, 2025 (date) — Reporting period end date
- April 28, 2025 (date) — Filing date
FAQ
What is the total interest income reported for the quarter ending March 31, 2025?
The filing indicates interest income from money market funds for the period January 1, 2024, to March 31, 2024, but specific dollar amounts for the 2025 period are not detailed in the header.
What is the nature of the relationship with GlaxoSmithKline?
GlaxoSmithKline is mentioned in the context of the period January 1, 2025, to March 31, 2025, suggesting an ongoing business relationship or collaboration.
What are the key financial metrics reported for the period ending March 31, 2025?
The header information highlights financial elements such as interest income and additional paid-in capital, but detailed financial statements are not included in this excerpt.
Are there any significant new collaborations or agreements mentioned in this filing?
The filing references Adimab LLC in conjunction with license and service agreements for the period January 1, 2025, to March 31, 2025, indicating continued or new partnership activities.
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on April 28, 2025 regarding iTeos Therapeutics, Inc..